BIOLOG-ID
The members of the Supervisory Board of Biolog-id elected Jean-Luc Bélingard as Chairman of the Supervisory Board of the company. He succeeds to its founder, Jean-Claude Mongrenier, who will assume the vice-presidency. This appointment comes into effect on January 1st , 2021.
Biolog-id has developed unique expertise in connected healthcare solutions and offers a breakthrough innovation that makes the life cycle of sensitive therapeutic products (red blood cell concentrates, platelets, plasma, chemotherapy preparations) more reliable, and secures their administration to patients.
Jean-Luc Bélingard is a seasoned industry leader with an international career in the pharmaceutical, life sciences and diagnostics sector. He comes with 40 years of experience with some of the largest pharmaceutical companies, notably at Roche where he was a member of the Group Executive Committee (Basel, Switzerland). Since 2011, he has served as CEO and then Chairman of bioMérieux before taking on, in 2018, the Vice-Presidency of Institut Mérieux.
"It is an honor and a responsibility for me to join and support Biolog-id in a new stage of its development. Biolog-id is a company with a promising future. It patented a connected solution, Medical Device certified, which offers great added value in terms of public healthcare, with significant economic and social impacts. It makes it possible to strengthen the safety of medical procedures, improve the working conditions of healthcare professionals, reduce operational costs and prevent the loss of sensitive health products. This set of added values is a guarantee of quality and safety for patients and healthcare establishments. By accepting this mandate as Chairman of the Supervisory Board, I hope, along with the management team and employees, to contribute to the success of this innovative company”, declares Jean-Luc Bélingard.
"As the founder of the company, I am happy to hand over my functions to Jean-Luc Bélingard, with whom I share the same vision of the company, based on humanist values. Biolog-id will benefit from its extensive experience in the pharmaceutical industry and its governance skills. In particular, he will be responsible for leading the introduction of Biolog-id on the Nasdaq, its listing being planned as of 2022 ", announces Jean-Claude Mongrenier.
"The appointment of Jean-Luc Bélingard as Chairman of the Supervisory Board will allow Biolog-id to benefit from a high-level leadership executive with an indisputable influence. This is an important appointment for the international development of the company and for its upcoming IPO. I am convinced that he will be able to capitalize on this flagship of the FrenchTech 120 to make it go through new major stages, "confirms Jacques Simonnet, founder of the Xerys Group which has already funded Biolog-id up to about fifty million euros and is preparing a capital increase of more than 20 million euros.
About Biolog-id
Biolog-id has designed an intelligent and patented solution for the management and traceability of sensitive healthcare products (red blood cell concentrates, plasma, platelets, chemotherapy preparations), in order to optimize their supply chain from donor to patient. Present in North America, Europe, the Middle East, India and the Asia-Pacific region, Biolog-id has about a hundred employees around the world. The Biolog-connect® solution is protected by more than 100 international patents. Biolog-id is the property of its founder and the Xerys Funds.
Web site: www.biolog-id.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005413/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aptiv Powers Intelligent Edge Applications From Automotive to Robotics at CES 20265.1.2026 07:01:00 CET | Press release
Showcase Features Aptiv Technologies Enabling Intelligent Cars, Commercial Vehicles, Robots, and Other Mission Critical ApplicationsImmersive Demos Highlight End-to-End AI for Autonomy, Personalized User Experience and Extensive Connectivity Aptiv PLC (NYSE: APTV),a global industrial technology company, will showcase at CES 2026 how its intelligent edge solutions enable devices to sense, think, and act in real time—while continuously optimizing performance throughout their lifecycle. This approach brings advanced computing and artificial intelligence closer to where data is generated, unlocking AI-driven solutions for transportation, robotics, aerospace, and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260104888341/en/ Aptiv Powers the Intelligent Edge from Automotive to Robotics at CES 2026 By processing data locally at the edge, rather than relying solely on centralized cloud systems, Aptiv’s solutions enable fas
Belkin styrker beskyttelsen af hverdagsenheder med en ny serie skærmbeskyttere og et Wear & Tear-program4.1.2026 18:00:00 CET | Pressemeddelelse
Belkin lancerer syv nye skærmbeskyttere, der er udviklet med proprietær Nano-Titan-teknologi for øget styrke mod daglige fald og ridser Et Wear and Tear-program skaber ro i sindet for forbrugere, der ønsker at udskifte deres produkter Forbrugerne kan nu personalisere deres skærmbeskyttere med Screen Skinz Belkin, et førende mærke inden for forbrugerelektronik i over 40 år, annoncerer i dag en ny klasse af løsninger til skærmbeskyttelse, et strategisk partnerskab og et helt nyt wear-and-tear-program, der styrker virksomhedens engagement i at beskytte enheder og give forbrugerne tryghed. Lanceringen omfatter syv nye skærmbeskyttere, et partnerskab med ScreenSkinz vedrørende personalisering, og et program til udskiftning af skærmbeskyttere beregnet til at give brugerne varig ro i sindet og sikre, at de produkter, de elsker, forbliver trygge, sikre og i den bedste form. Mød ScreenForce Titan-serien: Det ultimative inden for fuldskærmsbeskyttelse Titan SmartShield Titan SmartShield fungerer
Belkin præsenterer næste generation af opladere, strømtilbehør til gaming og meget mere på CES 20264.1.2026 18:00:00 CET | Pressemeddelelse
Belkin lancerer nye trådløse Qi2-opladere, powerbanks med høj kapacitet, kraftfulde hubs samt et opladningsetui til Nintendo Switch 2, der får debut på CES 2026 Belkin, et førende mærke inden for forbrugerelektronik i over 40 år, annoncerede i dag en ny serie af tilbehør, der er designet til at styrke, beskytte og forbedre den måde, folk arbejder, leger og er forbundet på. Den nye kollektion, som debuterer på CES 2026, omfatter avancerede powerbanks, Qi2 25 W trådløse opladere, en trådløs HDMI-dongle til problemfri deling af indhold og et opladningsetui af næste generation til Nintendo Switch 2. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260104854623/da/ Belkin unveils new products at CES 2026 Gaming Charging Case Pro til Nintendo Switch 2 (model ENA003) Udviklet til den ultimative gamingoplevelse på farten leverer Pro-etuiet strøm, beskyttelse og mobilitet samlet i én førsteklasses løsning. En udtagelig powerbank på 1
SINOVAC Provides Update on Antigua High Court Order and Auditor Engagement4.1.2026 16:13:00 CET | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today provided an update on the Antigua High Court’s interlocutory order governing the Company’s board composition and corporate actions pending trial, and announced the engagement of Zhonghua Certified Public Accountants LLP (“Zhonghua”), an affiliate of the global accounting network UHY International, as the Company’s independent auditor and registered public accounting firm. Update on Antigua High Court Order Further to the order issued by the Antigua High Court (the “Court”) previously disclosed by the Company in a press release dated December 17, 2025, the Court has updated its order to provide that directors Mr. Simon Anderson, Mr. Shan Fu, Mr. Shuge Jiao, Dr. Chiang Li, Mr. Yuk Lam Lo, Mr. Yumin Qiu, Mr. Yu Wang, Ms. Rui-Ping Xiao, Mr. Andrew Y. Yan and Mr. Weidong Yin (collectively, the “Board”), will comprise the Board of the Company until the trial liste
Sinovac Receives Nasdaq Notification Regarding Late Filing of 2025 Half-Year Report4.1.2026 16:00:00 CET | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has received a notification letter dated January 2, 2026 (the “Notification Letter”) from Nasdaq Listing Qualifications (“Nasdaq”), stating that the Company was not in compliance with Nasdaq’s Listing Rule 5250(c)(2) since the Company did not timely file a Form 6-K containing an interim balance sheet and income statement as of the end of its second quarter of year 2025. As previously disclosed, the Company received a delisting determination letter (the “Staff Determination”) from Nasdaq in November 2025. The Company requested a hearing before the Nasdaq Hearings Panel to appeal the Staff Determination on November 19, 2025. Nasdaq has informed the Company that the Nasdaq Hearings Panel will also consider the matter addressed in the Notification Letter at a hearing scheduled for January 8, 2026 at which the Company has been invited to present
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom